panorama prenatal test (Natera Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Natera Inc panorama prenatal test
Panorama Prenatal Test, supplied by Natera Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/panorama+prenatal+test/panorama+prenatal+test/pm39907938-75-24-20
Average 90 stars, based on 1 article reviews

panorama prenatal test - by Bioz Stars, 2026-09

90/100 stars

Images

Next-Generation Sequencing:

Article Title: Current status of non-invasive prenatal testing in Japan.
Article Snippet: Aim: The purpose of this study was to report the 3-year experience of a nationwide demonstration project to introduce non-invasive prenatal testing (NIPT) of maternal plasma for aneuploidy, and review the current status of NIPT in Japan.. Methods: Tests were conducted to detect aneuploidy in high-risk pregnant women, and adequate genetic counseling was provided.. The clinical data, test results, and pregnancy outcomes were recorded.

Microarray:

Article Title: Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment
Article Snippet: LifeLabs Genetics offers Natera's Panorama Prenatal Test. .. Dynacare offers Ariosa Diagnostics’ (owned by Hoffmann-La Roche) Harmony test ( ). table ft1 table-wrap mode="anchored" t5 Table 3: caption a7 Test Characteristic Panorama Prenatal Test Harmony Prenatal Test Manufacturer Natera Ariosa Diagnostics (Roche) Laboratory availability LifeLabs Dynacare Pregnancy population Can be performed in twin pregnancies, consanguineous couples, and singleton pregnancies conceived by in vitro fertilization, including egg-donor and surrogate pregnancies Should not be performed in people who have received a bone marrow transplant Can be performed in twin pregnancies, consanguineous couples, and singleton pregnancies conceived by in vitro fertilization, including egg-donor and surrogate pregnancies Should not be performed in people who have received a bone marrow or organ transplant, or in people who have metastatic cancer Analysis method Targeted approach Single nucleotide polymorphism Targeted approach Microarray-based digital analysis of selected regions (DANSR) Sensitivity reported by manufacturer Trisomy 21: >99.9% Trisomy 18: 98.2% Trisomy 13: >99% Monosomy X: 92.9% 22q11.2 deletion syndrome: 90% Microdeletion extended panel (1p36 deletion, 15q11–q13 deletions [Angelman syndrome and Prader-Willi syndrome], 5p deletion): 93.8% to >99% Trisomy 21: >99% Trisomy 18: 97.4% Trisomy 13: 93.8% Monosomy X: 94.3% False-positive rate reported by manufacturer a Trisomy 21: 0% Trisomy 18: <0.1% Trisomy 13: 0% Monosomy X: <0.1% Each microdeletion syndrome: <1% Trisomy 21: <0.1% Trisomy 18: <0.1% Trisomy 13: <0.1% Test timing As early as 9 weeks of pregnancy As early as 10 weeks of pregnancy Time to result Within 10 days Within 10 business days Out-of-pocket test cost b Trisomies 21, 18, and 13, and sex chromosome aneuploidies: $550 Plus 22q11.2 deletion: additional $195 Plus microdeletion extended panel: additional $245 Trisomies 21, 18, and 13, and sex chromosome aneuploidies: $495 Plus 22q11.2 deletion: additional $175 Open in a separate window a Systematic reviews suggest a higher false-positive rate than those reported by the manufacturers. ..

In Vitro:

Diagnostic Assay:

Article Title: Lab-on-a-chip technology: impacting non-invasive prenatal diagnostics (NIPD) through miniaturisation.
Article Snippet: This paper aims to provide a concise review of non-invasive prenatal diagnostics (NIPD) to the lab-on-a-chip and microfluidics community.. Having a market of over one billion dollars to explore and a plethora of applications, NIPD requires greater attention from microfluidics researchers.. In this review, a complete overview of conventional diagnostic procedures including invasive as well as non-invasive (fetal cells and cell-free fetal DNA) types are discussed.

Fluorescence In Situ Hybridization:

Article Title: Discordant circulating fetal DNA and subsequent cytogenetics reveal false negative, placental mosaic, and fetal mosaic cfDNA genotypes
Article Snippet: Verinata Health Inc also offers testing for Monosomy X (Turner Syndrome) as an additional option to the verifi(TM) prenatal test; C. MaterniT21TM Plus Test (Sequenom Center for Molecular Medicine, Grand Rapids, MI), utilizes massively parallel DNA sequencing to identify trisomy of chromosomes 21, 18, 13, 16, and 22; 22q deletion syndrome (DiGeorge), 5p (Cri-du-chat syndrome), 15q (Prader-Willi/Angelman syndromes), 1p36 deletion syndrome. .. D. Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070, (650) 249-9090] provides the Panorama prenatal test based upon single nucleotide polymorphisms. c The 4 CVS samples were further analyzed by FISH for chromosome 21 and chromosome 13 copy number. ..

Review